Novo Nordisk Faces a Summer of Dual Catalysts as Oral Wegovy and Medicare Converge
The Danish pharma giant is steering into a pivotal second half of 2026, with two powerful demand drivers…
Novo Nordisk’s Obesity Franchise Expands Reach as Comorbidity Data and Pipeline Catalysts Converge
Semaglutide reduces asthma exacerbations by 26% and migraine medication use by 7%. Stock rebounds 13% in 30 days;…